Roivant Sciences Reports Significant Revenue Decline and Improved Net Loss in Q2 FY 2025

Roivant Sciences Ltd. reported a significant decline in financial performance for the second quarter of fiscal year 2025, with revenues of $1.57 million, down from $4.48 million in the same period last year. For the six months ending September 30, 2025, total revenue was $3.74 million, a decrease from $12.47 million in the prior year. The company attributed this decline primarily to reduced income from license agreements, particularly at its subsidiary Genevant. Operating expenses for the quarter were $307.8 million, a decrease from $346.2 million in the previous year, driven by lower general and administrative costs.

The company reported a net loss of $166.0 million for the quarter, compared to a net loss of $279.9 million in the same period last year. The loss attributable to Roivant Sciences Ltd. was $113.5 million, a notable improvement from $230.2 million in the prior year. For the six-month period, the net loss was $440.0 million, compared to $222.4 million in the same period last year. The improvement in net loss was attributed to a decrease in general and administrative expenses and the absence of a significant gain from the sale of Telavant net assets, which had contributed $110.4 million to the previous year's results.

In terms of strategic developments, Roivant completed the sale of its majority-owned subsidiary Telavant in December 2023, which provided the company with approximately $5.2 billion in cash. As of September 30, 2025, Roivant reported cash, cash equivalents, and marketable securities totaling approximately $4.4 billion, down from $4.9 billion at the end of the previous fiscal year. The company continues to focus on advancing its pipeline of product candidates, including brepocitinib and IMVT-1402, with several clinical trials ongoing.

Operationally, Roivant's research and development expenses increased to $164.6 million for the quarter, up from $143.1 million in the prior year, reflecting ongoing investments in its product pipeline. The company reported a headcount increase to support its clinical studies, particularly in the anti-FcRn franchise. As of September 30, 2025, Roivant had approximately 689.7 million shares outstanding, with an accumulated deficit of $429.1 million.

Looking ahead, Roivant anticipates continued investment in its research and development activities, with expectations of increased expenses as it advances its product candidates through clinical trials. The company has indicated that while it does not currently require additional capital, it may seek to raise funds in the future to support its operations and strategic initiatives. The outlook remains cautious, with management acknowledging the inherent uncertainties in biopharmaceutical development and the potential need for additional financing to achieve its long-term goals.